Cargando…

Immunoinformatics Approach to Design a Multi-Epitope Vaccine against Cutaneous Leishmaniasis

Cutaneous Leishmaniasis (CL), a neglected vector-borne disease caused by protozoan parasite Leishmania major (L. major), is a major public health concern, and the development of new strategies to reduce the disease incidence has become a top priority. Advances in immunoinformatics and in-silico epit...

Descripción completa

Detalles Bibliográficos
Autores principales: Naz, Shumaila, Aroosh, Aiman, Caner, Ayse, Şahar, Esra Atalay, Toz, Seray, Ozbel, Yusuf, Abbasi, Sumra Wajid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967539/
https://www.ncbi.nlm.nih.gov/pubmed/36851219
http://dx.doi.org/10.3390/vaccines11020339
_version_ 1784897289928572928
author Naz, Shumaila
Aroosh, Aiman
Caner, Ayse
Şahar, Esra Atalay
Toz, Seray
Ozbel, Yusuf
Abbasi, Sumra Wajid
author_facet Naz, Shumaila
Aroosh, Aiman
Caner, Ayse
Şahar, Esra Atalay
Toz, Seray
Ozbel, Yusuf
Abbasi, Sumra Wajid
author_sort Naz, Shumaila
collection PubMed
description Cutaneous Leishmaniasis (CL), a neglected vector-borne disease caused by protozoan parasite Leishmania major (L. major), is a major public health concern, and the development of new strategies to reduce the disease incidence has become a top priority. Advances in immunoinformatics and in-silico epitope prediction could be a promising approach to designing a finest vaccine candidate. In this study, we aimed to design a peptide-based vaccine against CL using computational tools and identified ten B-cell-derived T-cell epitopes from the glycoprotein gp63 of L. major. All of the potential immunodominant epitopes were used to design a vaccine construct along with a linker and an adjuvant at the N-terminal for enhancing its immunogenicity. Additionally, many characteristics of the proposed vaccine were examined, and it was confirmed to be non-allergenic, non-toxic, and thermally stable. To assess the vaccine interaction with the innate immune toll-like receptor-4 (TLR-4), a 3D structure of the vaccine construct was developed. Molecular docking and molecular dynamic simulation were used to confirm the binding and to assess the stability of the vaccine-TLR4 complex and interactions, respectively. In conclusion, our multi-epitope vaccine will provide a gateway to analyze the protein function of a potential vaccine candidate against CL.
format Online
Article
Text
id pubmed-9967539
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99675392023-02-27 Immunoinformatics Approach to Design a Multi-Epitope Vaccine against Cutaneous Leishmaniasis Naz, Shumaila Aroosh, Aiman Caner, Ayse Şahar, Esra Atalay Toz, Seray Ozbel, Yusuf Abbasi, Sumra Wajid Vaccines (Basel) Article Cutaneous Leishmaniasis (CL), a neglected vector-borne disease caused by protozoan parasite Leishmania major (L. major), is a major public health concern, and the development of new strategies to reduce the disease incidence has become a top priority. Advances in immunoinformatics and in-silico epitope prediction could be a promising approach to designing a finest vaccine candidate. In this study, we aimed to design a peptide-based vaccine against CL using computational tools and identified ten B-cell-derived T-cell epitopes from the glycoprotein gp63 of L. major. All of the potential immunodominant epitopes were used to design a vaccine construct along with a linker and an adjuvant at the N-terminal for enhancing its immunogenicity. Additionally, many characteristics of the proposed vaccine were examined, and it was confirmed to be non-allergenic, non-toxic, and thermally stable. To assess the vaccine interaction with the innate immune toll-like receptor-4 (TLR-4), a 3D structure of the vaccine construct was developed. Molecular docking and molecular dynamic simulation were used to confirm the binding and to assess the stability of the vaccine-TLR4 complex and interactions, respectively. In conclusion, our multi-epitope vaccine will provide a gateway to analyze the protein function of a potential vaccine candidate against CL. MDPI 2023-02-02 /pmc/articles/PMC9967539/ /pubmed/36851219 http://dx.doi.org/10.3390/vaccines11020339 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Naz, Shumaila
Aroosh, Aiman
Caner, Ayse
Şahar, Esra Atalay
Toz, Seray
Ozbel, Yusuf
Abbasi, Sumra Wajid
Immunoinformatics Approach to Design a Multi-Epitope Vaccine against Cutaneous Leishmaniasis
title Immunoinformatics Approach to Design a Multi-Epitope Vaccine against Cutaneous Leishmaniasis
title_full Immunoinformatics Approach to Design a Multi-Epitope Vaccine against Cutaneous Leishmaniasis
title_fullStr Immunoinformatics Approach to Design a Multi-Epitope Vaccine against Cutaneous Leishmaniasis
title_full_unstemmed Immunoinformatics Approach to Design a Multi-Epitope Vaccine against Cutaneous Leishmaniasis
title_short Immunoinformatics Approach to Design a Multi-Epitope Vaccine against Cutaneous Leishmaniasis
title_sort immunoinformatics approach to design a multi-epitope vaccine against cutaneous leishmaniasis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967539/
https://www.ncbi.nlm.nih.gov/pubmed/36851219
http://dx.doi.org/10.3390/vaccines11020339
work_keys_str_mv AT nazshumaila immunoinformaticsapproachtodesignamultiepitopevaccineagainstcutaneousleishmaniasis
AT arooshaiman immunoinformaticsapproachtodesignamultiepitopevaccineagainstcutaneousleishmaniasis
AT canerayse immunoinformaticsapproachtodesignamultiepitopevaccineagainstcutaneousleishmaniasis
AT saharesraatalay immunoinformaticsapproachtodesignamultiepitopevaccineagainstcutaneousleishmaniasis
AT tozseray immunoinformaticsapproachtodesignamultiepitopevaccineagainstcutaneousleishmaniasis
AT ozbelyusuf immunoinformaticsapproachtodesignamultiepitopevaccineagainstcutaneousleishmaniasis
AT abbasisumrawajid immunoinformaticsapproachtodesignamultiepitopevaccineagainstcutaneousleishmaniasis